WO2023044016A3 - Conjugués d'anticorps immunostimulants et leur utilisation - Google Patents

Conjugués d'anticorps immunostimulants et leur utilisation Download PDF

Info

Publication number
WO2023044016A3
WO2023044016A3 PCT/US2022/043820 US2022043820W WO2023044016A3 WO 2023044016 A3 WO2023044016 A3 WO 2023044016A3 US 2022043820 W US2022043820 W US 2022043820W WO 2023044016 A3 WO2023044016 A3 WO 2023044016A3
Authority
WO
WIPO (PCT)
Prior art keywords
conjugates
stimulant
antibody immune
antibody
immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2022/043820
Other languages
English (en)
Other versions
WO2023044016A2 (fr
Inventor
Wen Zhang
Zhaopeng SUN
Xixin HU
Xiwu HUI
Mo DAN
Can YUAN
Lu LV
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSPC Dophen Corp
Original Assignee
CSPC Dophen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSPC Dophen Corp filed Critical CSPC Dophen Corp
Publication of WO2023044016A2 publication Critical patent/WO2023044016A2/fr
Publication of WO2023044016A3 publication Critical patent/WO2023044016A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne, dans certains modes de réalisation, des conjugués d'anticorps immunostimulants pour l'immunothérapie anticancéreuse. L'invention concerne également des procédés de fabrication et d'utilisation desdits conjugués d'anticorps immunostimulants.
PCT/US2022/043820 2021-09-17 2022-09-16 Conjugués d'anticorps immunostimulants et leur utilisation Ceased WO2023044016A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163245331P 2021-09-17 2021-09-17
US63/245,331 2021-09-17

Publications (2)

Publication Number Publication Date
WO2023044016A2 WO2023044016A2 (fr) 2023-03-23
WO2023044016A3 true WO2023044016A3 (fr) 2023-04-20

Family

ID=85603533

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/043820 Ceased WO2023044016A2 (fr) 2021-09-17 2022-09-16 Conjugués d'anticorps immunostimulants et leur utilisation

Country Status (1)

Country Link
WO (1) WO2023044016A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120294885A1 (en) * 2011-05-18 2012-11-22 The University Of Kansas Toll-like receptor-7 and -8 modulatory 1h imidazoquinoline derived compounds
US20210017238A1 (en) * 2018-04-03 2021-01-21 Sanofi Antigenic OspA Polypeptides
WO2021086981A1 (fr) * 2019-10-29 2021-05-06 Cspc Dophen Corporation Compositions et méthodes de traitement du cancer au moyen d'un conjugué anticorps-médicament anti-her2
US20210154316A1 (en) * 2018-05-17 2021-05-27 Bolt Biotherapeutics, Inc. Immunoconjugates

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120294885A1 (en) * 2011-05-18 2012-11-22 The University Of Kansas Toll-like receptor-7 and -8 modulatory 1h imidazoquinoline derived compounds
US20210017238A1 (en) * 2018-04-03 2021-01-21 Sanofi Antigenic OspA Polypeptides
US20210154316A1 (en) * 2018-05-17 2021-05-27 Bolt Biotherapeutics, Inc. Immunoconjugates
WO2021086981A1 (fr) * 2019-10-29 2021-05-06 Cspc Dophen Corporation Compositions et méthodes de traitement du cancer au moyen d'un conjugué anticorps-médicament anti-her2

Also Published As

Publication number Publication date
WO2023044016A2 (fr) 2023-03-23

Similar Documents

Publication Publication Date Title
MX2024011292A (es) Conjugados de camptotecina.
WO2019241430A3 (fr) Conjugués anticorps-oligonucléotide
SG170091A1 (en) Anti-5t4 antibodies and uses thereof
MX2023013995A (es) Conjugados de anticuerpo y antraciclina.
WO2021163064A3 (fr) Anticorps et protéines de fusion se liant à ccr8, et leurs utilisations
EP4527466A3 (fr) Récepteurs antigéniques chimériques anti-dll3 et leurs utilisations
WO2019178269A3 (fr) Anticorps qui se lient à cd39 et leurs utilisations
WO2021055577A3 (fr) Anticorps anti-klk7, anticorps anti-klk5, anticorps multispécifiques anti-klk5/klk7, et leurs procédés d'utilisation
NO20083127L (no) Fremgangsmater og preparater for malretting av polyubiquitin
TW200616662A (en) Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates
EP4681726A3 (fr) Anticorps anti-par2 et leurs utilisations
WO2023169896A8 (fr) MOLÉCULES DE LIAISON DIRIGÉES CONTRE LE FRα
WO2020225805A3 (fr) Constructions d'anticorps tri-spécifiques précurseurs et leurs procédés d'utilisation
WO2022051591A3 (fr) Anticorps anti-nectine-4 et leurs utilisations
WO2020247929A8 (fr) Anticorps anti-cd3 à haute affinité et leurs méthodes de génération et d'utilisation
WO2024073723A3 (fr) Anticorps anti-cd122 et leurs utilisations
CA3242972A1 (fr) Anticorps anti-ror1, conjugue anticorps anti-ror1-medicament et leurs utilisations medicales
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
MX2025002569A (es) Anticuerpos anti-trop2/egfr y usos de estos
EP4588524A3 (fr) Anti-tigit et anti-pvrig dans des traitements de monothérapie et de combinaison
WO2021207948A9 (fr) Anticorps dirigés contre le sars-cov-2 et leurs utilisations
WO2022099100A3 (fr) Protéines de liaison reconnaissant l'antigène ha-1 et leurs utilisations
MX2025005092A (es) Anticuerpo anti-trem2 y usos del mismo
MX2024013871A (es) Agentes aglutinantes 5t4 y usos de los mismos
MY150643A (en) Methods and compositions for targeting hepsin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22870753

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22870753

Country of ref document: EP

Kind code of ref document: A2